Qilian International Holding Group Limited (QLI)
| Market Cap | 306.25M |
| Revenue (ttm) | 46.70M |
| Net Income (ttm) | 5.07M |
| Shares Out | 35.00M |
| EPS (ttm) | 0.14 |
| PE Ratio | 60.43 |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $8.75 |
| Previous Close | $9.29 |
| Change ($) | -0.54 |
| Change (%) | -5.81% |
| Day's Open | 10.14 |
| Day's Range | 8.62 - 10.95 |
| Day's Volume | 3,157,215 |
| 52-Week Range | 8.62 - 12.02 |
News
Jiuquan, China, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Qilian International Holding Group Limited (the “Company”) (Nasdaq: QLI), a China-based pharmaceutical and chemical products manufacturer, tod...
Qilian (QLI) is catching the eyes of investors on Tuesday as shares of its stock started trading today via the company's IPO. The post Qilian IPO: 10 Things for Potential QLI Stock Investors t...
Jiuquan, China, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Qilian International Holding Group Limited (the “Company”), a China-based pharmaceutical and chemical products manufacturer, today announced t...
About QLI
Qilian International Holding Group Limited engages in the research, development, and production of active pharmaceutical ingredients (APIs) and traditional Chinese medicine derivative (TCMD) products in China. The company offers licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licor... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | IPO Date Jan 12, 2021 |
| CEO Zhanchang Xin | Employees 279 |
| Stock Exchange NASDAQ | Ticker Symbol QLI |
Financial Performance
In 2019, QLI's revenue was $46.10 million, a decrease of -8.48% compared to the previous year's $50.37 million. Earnings were $5.33 million, an increase of 3.15%.